Table 5. List of top ten vaccines for total adverse event reports following immunization and total number of reports and serious adverse events when vaccine administered alone, 2013–2016.
| Vaccine group | Vaccine trade name | Reporting rate per 100,000 doses distributed | Reports vaccine administered alone |
Reports of SAEs from vaccine administered alonea | |||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | Ratea | ||
| Meningococcal serogroup C conjugate | Meningitec® Menjugate® Neis Vac-C® | 1,346 | 91.6 | 33 | 2 | 4 | 0.3 |
| Diphtheria, tetanus toxoid, acellular pertussis, inactivated poliomyelitis | Quadracel® Infanrix™-IPV | 167 | 76.8 | 92 | 55 | 4 | 1.8 |
| Diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, inactivated poliomyelitis, haemophilus type b | Infanrix hexa™ | 462 | 65.9 | 35 | 8 | 2 | 0.3 |
| Pneumococcal conjugate | Prevnar® Synflorix™ Prevnar® 13 | 2,098 | 64.4 | 64 | 3 | 5 | 0.2 |
| Measles, mumps, rubella, varicella | Priorix-Tetra™ Proquad™ | 1,075 | 59.8 | 86 | 8 | 11 | 0.6 |
| Meningococcal B | Bexsero® | 212 | 57.1 | 160 | 75 | 17 | 4.6 |
| Haemophilus influenzae type b conjugate | ACT-HIB® Hiberix® Liquid PedvaxHib® | 39 | 45.9 | 4 | 10 | 0 | 0.0 |
| Rabies | Imovax® Rabies RabAvert® | 80 | 43.2 | 64 | 80 | 4 | 2.2 |
| Pneumococcal polysaccharide | Pneumo® 23 Pneumovax® 23 | 915 | 42.9 | 452 | 50 | 28 | 1.3 |
| Diphtheria, tetanus toxoid, acellular pertussis, inactivated poliomyelitis, Haemophilus type b | Pediacel® Infanrix™ - IPV/HIB Pentacel® | 1,512 | 40.7 | 422 | 28 | 38 | 1.0 |
Abbreviations: N, number; SAE, serious adverse events
a Rate is per 100,000 doses distributed